BioSpace News Archive

Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

As a first-in-the-world “rapid smart test kit”, the cPass™ which can measure neutralising antibodies in an hour will be a huge boost to current COVID-19 investigations, from contact tracing, sero-prevalence survey, and assessment of herd immunity, longevity of protective immunity and efficacy of different vaccine candidates.

Rezolute, Inc., announced an update on the potential impact of the global COVID-19 pandemic on the Company’s clinical and business operations.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, named cell therapy and oncology expert Jakob Dupont, M.D. as Executive Vice President, Global Head of Research and Development.

Neuraptive Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries, announced that the U.S. Food and Drug Administration has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve injuries.

Akumin Inc. held its annual general and special meeting of shareholders , May 14, 2020, on a virtual meeting platform.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2020. Results are presented in Canadian dollars unless otherwise noted. “The past two months have been especially trying for our residents, clients, frontline workers and their families,” said President and Chief Executive Officer, Dr. Michael Guerriere. “I want to express my heartfelt thanks to our team for their ongoing

Boston Scientific Corporation announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company’s shelf registration statement.

Abbott’s ID NOW™ is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they’re needed